Skip to content

Regeneron teams with Roche to triple supply of its COVID-19 drug

August 19, 2020

Regeneron (NASDAQ:REGN) has teamed up with Roche (OTCQX:RHHBY) to increase the supply of its COVID-19 drug via a new production/distribution deal.

The two will collaborate on developing and manufacturing REGN-COV2 – Regeneron’s investigational two-antibody “cocktail” now in late-stage clinical trials – with Regeneron handling U.S. distribution and Roche taking care of distribution outside the U.S.

That should increase overall capacity of REGN-COV2 by 3.5 times, they say, if regulators approve.

Initial study results are expected by the end of September, which could precede an emergency authorization by year-end.

The two will dedicate a certain manufacturing capacity to REGN-COV2 each year, and have already begun the technology transfer.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: